trovafloxacin sold trovan pfizer turvel laboratorios almirall broad spectrum antibiotic inhibits uncoiling supercoiled dna various bacteria blocking activity dna gyrase topoisomerase withdrawn market due risk hepatotoxicity better grampositive bacterial coverage less gramnegative coverage previous fluoroquinolones trovafloxacin use significantly restricted due high potential inducing serious sometimes fatal liver currently drug approved use us european union due association cases acute liver failure death key reaction building ring consists cycloaddition ethyl diazoacetate afford pyrrazolidine pyrolysis results loss nitrogen formation cyclopropylpyrrolidine ring stereochemistry ring simply reflects thermodynamics since cis ring fusion far stable arrangement cis configuration ester group ester saponified corresponding carboxylic acid acid undergoes version curtius rearrangement treated diphenylphosphoryl azide dppa afford transient isocyanate reactive function adds tbuoh reaction medium afford product tertbutyloxycarbonyl protecting group derivative catalytic hydrogenation removes carbobenzyloxy protecting group afford secondary amine standard quinoline reaction amine used displace reactive fluorine ethyl us food drug administration approved trovafloxacin therapeutic use december use patients aged years june agency advised doctors limit prescription trovafloxacin due adverse events associated drug cases acute liver injury reported fda may fda withdrew marketing authorisation trovafloxacin trovafloxacin received marketing authorisation european union october june view reported adverse events committee proprietary medicinal products recommended suspension marketing authorisation suspension took effect august renewed september october pfizer notified european commission decision voluntarily withdraw marketing authorisation approved ema march trovan sales first full year market contributed million pfizers total revenue billion investors expected eventually bring billion per meningitis epidemic kano nigeria drug administered approximately infected children eleven children died trial five taking trovan six taking older antibiotic used comparison clinical trial others suffered blindness deafness brain damage common consequences meningitis seen patients treated trovafloxacin infection investigation washington post concluded pfizer administered drug part illegal clinical trial without authorization nigerian government consent childrens case came light december result investigation washington post sparked significant public outcry serious error falsification backdating ethics approval letter lead investigator trial dr abdulhamid isa dutse dr dutse chief medical officer aminu kano teaching hospital result trial children treated oral trovafloxacin mortality rate compared mortality rate intramuscular ceftriaxone victims trovan tests nigeria filed series unsuccessful lawsuits united states however january united states court appeals second circuit ruled nigerian victims families entitled bring suit pfizer united states alien tort statute million settlement state kano reached july additionally two lawsuits also remain pending new york united according wikileaked us embassy cables pfizers country manager admitted pfizer hired investigators uncover corruption links federal attorney general michael aondoakaa expose put pressure drop federal httpsenwikipediaorgwikitrovafloxacin